ESLA Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Chartmill - Mentions: TGE HTZ DENN KFRC ...

Tuesday's session: top gainers and losers

10 days ago - By: Chartmill - Mentions: TGE QURE TCRX MTC ...

Which stocks are moving on Monday?

9 days ago - By: Benzinga - Mentions: MYGN SRPT EVOK TCMD ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

10 days ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

22 days ago - By: Benzinga - Mentions: SLP IBIO PRPH ARCT ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

5 months ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

5 months ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

6 months ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

8 months ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

9 months ago - By: Stocktwits - Mentions: CADL SLRN SLDB ADTX

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

9 months ago - By: Estrella Immunopharma

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

9 months ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

a year ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

a year ago - By: Estrella Immunopharma, Inc.

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

a year ago - By: InvestorPlace - Mentions: ADGM AGBA AKAN CONN ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

1 years ago - By: InvestorPlace

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

2 years ago - By: InvestorPlace - Mentions: CPRX VNRX

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

2 years ago - By: InvestorPlace - Mentions: VLCN CRGE AERT JTAI ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

2 years ago - By: InvestorPlace - Mentions: MBI XCUR FLJ CURV ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

2 years ago - By: InvestorPlace - Mentions: SPCB MOB IMUX TSBX ...

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock News

ESLA Latest News, Press Relases and Analysis

Tuesday's session: top gainers and losers

Which stocks are moving on Monday?

12 Health Care Stocks Moving In Tuesday's Intraday Session

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

12 Health Care Stocks Moving In Wednesday's Intraday Session

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday